Alkahest reveals positive outcomes from Phase 2 study of GRF6019
Category: #health  By Mateen Dalal  Date: 2019-08-07
  • share
  • Twitter
  • Facebook
  • LinkedIn

Alkahest reveals positive outcomes from Phase 2 study of GRF6019

The study cites that dosing with GRF6019 were harmless and well-tolerated in patients with Alzheimer’s disease dementia (AD).

Alkahest, Inc., a clinical-stage biopharmaceutical company focused on researching and creating transformative therapies to cure age-related diseases, recently shared top-line data from its Phase 2 clinical trial of GRF6019 in mild to moderate Alzheimer’s disease dementia (AD).

According to sources, the study was developed to evaluate the tolerability, safety and potential therapeutic effects of multiple doses of GRF6019 in patients with mild to moderate AD over six months. Subjects for this study were randomly selected and treated intravenously with a dose of 100mL or 250mL of GRF6019 for five days for first week and once more for five continuous days during Week 13, with an interval of 12 weeks following each dose.

Sources cite that patients receiving GRF6019 in the secondary endpoint showed no deterioration in cognition, as measured by the Mini-Mental State Examination (MMSE) and the 11-item ADAS-Cog11 (AD Assessment Scale-cognitive subscale), and slight decline in function by the Clinical Dementia Rating scale Sum-of-Boxes (CDR-SB) score and the AD Cooperative Study Activities of Daily Living scale 23-item version (ADCS-ADL23).

Speaking on the move, Dr. Karoly Nikolich, Chief Executive Officer, Alkahest, said that these results show potential benefit of this plasma protein fraction in reducing the progression of cognitive decline in patients with mild to moderate AD.

He added that development of impactful treatments for Alzheimer and other neurodegenerative diseases of aging have failed for decades, however, GRF6019 displays an innovative approach to successfully treating Alzheimer’s disease by focusing on multiple underlying mechanisms of disease and the data fuels the development of GRF6019 and more therapies for AD.  

For the uninitiated, Alkahest focuses on treating age-related diseases and neurodegenerative with advanced therapies targeting the aging plasma proteome. The company’s pipeline contains numerous therapeutic candidates like protein-targeted interventions which intends to reduce the biological processes of aging.

Source Credit: https://www.alkahest.com/alkahest-announces-positive-top-line-data-from-phase-2-study-in-mild-to-moderate-alzheimers-disease/

 

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Mercedes-AMG Petronas F1 Team and AMD team-up for F1 2020
Mercedes-AMG Petronas F1 Team and AMD team-up for F1 2020
By Mateen Dalal

Mercedes-AMG Petronas F1 Team, and Advanced Micro Devices (AMD), a renowned semiconductor developer, have reportedly announced a new multi-year partnership agreement that has combined the two firms’ passion of for high performance, beginning fr...

Aduro begins trial of MK-5890 for non-small cell lung cancer treatment
Aduro begins trial of MK-5890 for non-small cell lung cancer treatment
By Mateen Dalal

The biopharmaceutical giant has also received a USD 10 million development milestone payment from Merck & CO. for the initiation of the trial A clinical-stage biopharmaceutical company, Aduro Biotech, Inc. recently announced to have ba...

TherapeuticsMD submits a New Drug Application to the FDA for BIJUVA®
TherapeuticsMD submits a New Drug Application to the FDA for BIJUVA®
By Mateen Dalal

TherapeuticsMD, Inc., an inventive pharmaceutical company that focuses on women healthcare, has recently announced that it has presented a New Drug Application (NDA) pre-approval efficacy supplement to the U.S. FDA (Food and Drug Administration) for ...